Sciecure has been devoting on the development, manufacturing, and sale for the new and generic drugs with the high quality for both the domestic and international markets. Some have been passed the inspections by CFDA. With the growing demanding, our company has focused to develop the overseas markets in the pharmaceutical field, a number of these products has been submitted in Europe and USA.
1. Marketing Authorization（MA）of Aripiprazole 5mg, 10mg, 15mg, and 30mg tablets are granted by UK MHRA on 30th September, 2016.
2. Marketing Authorization (MA) of Voriconazole 50mg and 200mg tablets are granted by UK MHRA on 7 October, 2016.
3. Marketing Authorization（MA）of Pregabalin 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg hard capsules are granted by UK MHRA on 20 January 2017.
These are the great achievements for our company, and we will continue to develop more high quality drugs to benefit the societies.
Prev：Marketing Authorization（MA）of Levetiracetam 100mg/ml concentrate for solution for infusion is granted by Germany Federal Institute for Drugs and Medical Devices
Next：Marketing Authorization (MA) of Levetiracetam Sciecure 100mg/ml concentrate for solution for infusion is granted by UK MHRA